Amicus Therapeutics — Q3 2023 Earnings Presentation
23 slides from Amicus Therapeutics's earnings presentation, Nov 8, 2023
Slide 1: 3Q23 Results Conference Call & Webcast
AT T H E F O R E F RO N T O F THERAPIES FOR RARE DISEASES 3Q23 Results Conference Call & Webcast November 8, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and c
Slide 3: A Rare Company
A Rare Company Patient-dedicated, rare disease biotech company with sustained double-digit revenue growth, a global commercial infrastructure, and late-stage development capabilities World-class Clinical Gene Therapy Non-GAAP GLOBAL Development Platform PROFITABILITY COMMERCIAL Capabilities Leveragi
Slide 4: Strategic Priorities
2023 1 Galafold® revenue growth of 12-17% at CER1, now raised to 16-18% Strategic Priorities 2 Secure FDA, EMA, and MHRA approvals for Pombiliti™ + Opfolda™ 3 Initiate successful global launches of Pombiliti™ + Opfolda™ Advance best-in-class, next-generation Fabry and Pompe pipeline 4 programs and c
Slide 5: Galafold (migalastat) Continued Growth
Galafold® (migalastat) Continued Growth Building a leadership position in the treatment of Fabry disease 5
Slide 6: 2023 Galafold Success
2023 Galafold Success (as of September 30, 2023) Galafold quarterly revenue surpasses $100M for the first time in 3Q23 Galafold is the first and only approved oral treatment option with a unique mechanism of action for Fabry patients with amenable variants 100.7M $ 3Q23 Galafold 60% Revenue Share of
Slide 7: Galafold Performance
Galafold Performance Galafold YTD reported revenue growth of +17% to $281M $381M - $388M2 $329M1 3Q23 revenue growth of +19% at CER $306M $261M Q4 $88M Global mix of switch (~42%) and previously Q3 untreated patients (~58%)3 $101M Q3 $182M Compliance and adherence over 90% $82M Q2 Q2 $94M $91M
Slide 8: Galafold Global Commercial Momentum
Galafold Global Commercial Momentum (as of September 30, 2023) Strong patient demand and performance against key metrics lay the foundation for continued double-digit growth in 2023 Sustained Growth in 2023 Driven by: Continued penetration into existing markets Further uptake in naïve population and
Slide 9: Pombiliti + Opfolda
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Potential to establish a new standard of care for people living with Late-onset Pompe disease 9
Slide 10: NOW APPROVED
NOW APPROVED In the U.S., EU, & U.K. 10
Slide 11: Global Launch of Pombiliti + Opfolda Successfully Underway
Global Launch of Pombiliti + Opfolda Successfully Underway 60+ patients on commercial therapy as of early November; Early days of launch exceeding expectations providing strong foundation for 2024 Performance KOL and Patient Access and Outreach Reimbursement Patient Demand Promotion Positive Interac
Slide 12: Conversion of EAP and Clinical Trial Patients
Conversion of EAP and Clinical Trial Patients to Pombiliti + Opfolda Well on-track to transition all clinical trial and expanded access patients to commercial supply by year end Expanded access and clinical trial conversions progressing ahead of schedule in each respective launch country: – German
Slide 13: Additional Regulatory and Clinical Updates
Additional Regulatory and Clinical Updates Building the body of evidence through ongoing clinical studies and expanding commercial access through multiple regulatory submissions Multiple regulatory submissions expected in 2024 Ongoing clinical studies in children and adolescents1 with LOPD and i
Slide 14: Corporate Outlook
Corporate Outlook Delivering on our mission for patients and shareholders 14
Slide 15: 3Q 2023 Select Financial Results
3Q 2023 Select Financial Results 3Q23 revenue of $103.5M, up 22% at CER, and net loss significantly reduced (in thousands, except per share data) Sep. 30, 2023 Sep. 30, 2022 Product Revenue $103,501 $ 81,691 Cost of Goods Sold 9,946 13,436 R&D Expense 40,704 52,970 SG&A Expense 65,651 47,272 Changes
Slide 16: Financial Outlook and Path to Profitability
Financial Outlook and Path to Profitability Clear strategy to build our business, advance our portfolio, and achieve profitability Sustain Revenue Successfully Launch Deliver on Growth Pombiliti + Opfolda Financial Goals YTD total revenue Focused on prudent of $284.3M, expense management Galafold an
Slide 17: Positioned for Significant Value Growth
Positioned for Significant Value Growth Focused on execution and driving sustainable double-digit revenue growth on path to profitability Continue to Successful launch Advance Fully leverage Achieve bring Galafold of Pombiliti + next-generation global non-GAAP to as many Opfolda for therapies capabi
Slide 18: Appendix
Appendix
Slide 19: Reconciliation of Non-GAAP Financial Measures
Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) Total operating expenses - as reported GAAP Research and development: Stock-based compensation Selling, general and administrative: Stock-based compensation Loss on impairment of assets Changes in fair va
Slide 20: Environmental, Social, & Governance Snapshot
Environmental, Social, & Governance (ESG) Snapshot Who We Serve Environmental Our mission is to Diversity, Equity, & Management drive sustainability with our partners Inclusion (DEI) Address a rare genetic disease by incorporating Programs we Committed to producing Pledge to support a more inclusive
Slide 21: FX Sensitivity and Galafold Distribution of Quarterly Sales
FX Sensitivity and Galafold Distribution of Quarterly Sales Impact from Foreign Currency Q3 2023 Currency Variances: Q3 2022 Q3 2023 YoY Variance USD/ EUR 1.008 1.088 8.0% Distribution of Galafold Revenue GBP by Quarter over Past 5 years: 1.177 1.266 7.5% JPY 0.007 0.007 (4.4%) Q1 Q2 Q3 Q4 5 Year Av
Slide 22: Amicus Pipeline
Amicus Pipeline Streamlined rare disease pipeline with focus on Fabry disease and Pompe disease franchises INDICATION D I S C O V E R Y P R E C L I N I C A L P H A S E 1 / 2 P H A S E 3 R E G U L A T O R Y C O M M E R C I A L FAB RY F RANC H IS E Galafold® (migalastat) Fabry Gene Therapy Next-Genera
Slide 23: Thank you
Thank you